With policy support, the innovation of traditional Chinese medicine has shown an accelerating trend
.
Some analysts said that with the paving of policies and systems, after years of accumulation and efforts, Chinese medicine enterprises have begun to enter the stage of realizing results, and the listing of new Chinese medicines will continue to break out
in the future.
As October is about to end and the disclosure of the third quarterly report is nearing the end, the author combed through and found that a number of companies said that they insisted on the innovative research and development of traditional Chinese medicine, as well as the core products of innovative traditional Chinese medicine, and achieved growth
in the third quarter.
For example, Fangsheng Pharmaceutical said in the third quarter performance report released on the evening of October 30 that the third quarter report of 2022 benefited from the continuous focus on the main business of innovative traditional Chinese medicine in recent years, and its new quarterly performance reached a new high
.
Data show that in the first three quarters of this year, Fangsheng Pharmaceutical achieved a year-on-year increase of 21.
99% in operating income to 1.
357 billion yuan, and a net profit attributable to shareholders of listed companies increased by 317.
50% year-on-year to 259 million yuan
.
Among them, in the third quarter, the operating income increased by 26.
43% year-on-year to 484 million yuan; the net profit attributable to shareholders of listed companies increased by 893.
16% year-on-year, nearly 200 million yuan
.
Yiling Pharmaceutical said that it combines traditional Chinese medicine with modern science and technology, promotes the research and development of new drugs with theoretical originality, and forms a five-in-one innovative development model of traditional Chinese medicine of "theory-clinical-scientific research-industry-teaching", and has embarked on a model of
traditional Chinese medicine inheritance and innovation.
On October 28, it issued an announcement that in the third quarter, the company's total operating income increased by 7.
41% year-on-year to 2.
380 billion yuan; the net profit attributable to shareholders of listed companies increased by 40.
92% year-on-year to 366 million yuan; and the net profit of non-attributable parent increased by 49.
32%
year-on-year.
In addition, Wellcome Pharmaceutical also said that it attaches great importance to the research and development and innovation of traditional Chinese medicine, and achieved operating income of 474 million yuan and net profit attributable to the parent of 94 million yuan in the first three quarters of this year, a year-on-year increase of 1.
31%.
In the third quarter, the operating income was 179 million yuan, an increase of 5.
39% year-on-year and 59.
81% month-on-month, and the net profit attributable to the parent was 37 million yuan, a year-on-year increase of 27.
63% and an increase of 8.
45%
month-on-month.
Industry insiders believe that thanks to the continuous investment in the traditional Chinese medicine industry for many years and technology research and development, coupled with the forward-looking layout and orderly promotion of the big health industry, Wellcome Pharmaceutical has great development potential
during the period of high prosperity of the traditional Chinese medicine industry.
It is understood that Fangsheng Pharmaceutical is committed to building a health industry group with innovative Chinese medicine as the core, and driving the continuous improvement
of the company's core competitiveness with the two-wheel drive of "innovative Chinese medicine research and development" and "management change".
In recent years, Fangsheng Pharmaceutical has continued to focus on the main business of innovative traditional Chinese medicine, and launched the "338 Project" - to create 3 large products of 1 billion yuan, 3 large products of 500 million yuan and 8 products of more than 100 million yuan
.
With the corporate tenet of "inheriting innovation and benefiting mankind", Ling Pharmaceutical has continuously increased the depth of scientific research strength, and the capital investment has increased year after year, and the R&D investment in 2016~2021 has continued to increase, with the investment amount of 240 million yuan, 260 million yuan, 360 million yuan, 520 million yuan, 740 million yuan and 840 million yuan
respectively.
The injection of a large amount of funds has provided fertile soil for scientific research and innovation, built a number of advanced research and development platforms, and deployed
in multiple disease fields.
It is reported that the company has developed and listed 13 innovative traditional Chinese medicines, covering cardiovascular and cerebrovascular diseases, respiratory diseases, tumors, diabetes and other major diseases
.
Wellcome Pharmaceutical also attaches great importance to the R&D and innovation of traditional Chinese medicine in the process of development, data show that the company's R&D expenses in the first three quarters increased by 80.
05% year-on-year, reaching 28.
0673 million yuan, and the company focused on new drug research and development and secondary development of key products
.
In recent years, a number of substantial favorable policies of traditional Chinese medicine have been implemented, which has promoted the innovative drugs of traditional Chinese medicine into the fast lane
.
In recent years, the pace of review and approval of innovative Chinese medicine drugs has accelerated significantly, and 2021 is a clear upward inflection point
.
Data shows that since 2017, a total of 19 innovative Chinese medicine drugs have been approved, of which a total of 8 products were approved for marketing in 2021, the number of which is the sum
of the previous four years.
It is believed that under the impetus of favorable policies, more and more innovative products of traditional Chinese medicine will come out in the future, and enterprises will also usher in better development
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];